drugset

drugset / Trial / NCT02859012

Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

NCT02859012 ↗

Phase 2 Completed 60 enrolled Seoul National University Hospital

RandomizedCrossoverOpen-labelTreatment

Summary

To understand efficacy of axitinib in recurred or metastatic adenoid cystic carcinoma

Timeline

Start: 2016-09
Primary completion: 2017-12
Completion: 2020-08

Publications

Kang EJ, Ahn MJ, Ock CY, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Nam BH, Kim SB, Keam B. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2021 Oct 1;27(19):5272-5279. doi: 10.1158/1078-0432.CCR-21-1061.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axitinib	Small molecule	5 mg	Oral

Indications